PFM Health Sciences LP lowered its stake in Adaptimmune Therapeutics plc (NASDAQ:ADAP) by 7.2% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,501,303 shares of the biotechnology company’s stock after selling 193,466 shares during the period. PFM Health Sciences LP’s holdings in Adaptimmune Therapeutics were worth $13,282,000 at the end of the most recent quarter.
A number of other institutional investors also recently modified their holdings of the business. Point72 Asset Management L.P. boosted its position in Adaptimmune Therapeutics by 13.0% in the first quarter. Point72 Asset Management L.P. now owns 1,978,234 shares of the biotechnology company’s stock valued at $10,504,000 after buying an additional 228,234 shares in the last quarter. Odey Asset Management Group Ltd acquired a new stake in Adaptimmune Therapeutics in the first quarter valued at approximately $2,925,000. Man Group plc boosted its position in Adaptimmune Therapeutics by 30.7% in the first quarter. Man Group plc now owns 135,212 shares of the biotechnology company’s stock valued at $718,000 after buying an additional 31,740 shares in the last quarter. Schonfeld Strategic Advisors LLC acquired a new position in shares of Adaptimmune Therapeutics during the first quarter worth $1,873,000. Finally, Stifel Financial Corp lifted its holdings in shares of Adaptimmune Therapeutics by 9.8% during the first quarter. Stifel Financial Corp now owns 33,613 shares of the biotechnology company’s stock worth $178,000 after purchasing an additional 2,987 shares during the period. Hedge funds and other institutional investors own 75.53% of the company’s stock.
A number of brokerages have recently commented on ADAP. Barclays began coverage on shares of Adaptimmune Therapeutics in a report on Friday, May 28th. They set an “underweight” rating and a $4.00 price target on the stock. SVB Leerink reiterated a “hold” rating on shares of Adaptimmune Therapeutics in a report on Sunday, May 23rd. One research analyst has rated the stock with a sell rating, three have issued a hold rating and one has given a buy rating to the stock. Adaptimmune Therapeutics currently has an average rating of “Hold” and an average target price of $15.31.
Adaptimmune Therapeutics (NASDAQ:ADAP) last announced its earnings results on Wednesday, May 5th. The biotechnology company reported ($0.24) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.01. Adaptimmune Therapeutics had a negative net margin of 3,847.09% and a negative return on equity of 38.96%. The business had revenue of $0.43 million during the quarter, compared to the consensus estimate of $0.75 million. As a group, analysts anticipate that Adaptimmune Therapeutics plc will post -1 earnings per share for the current year.
Adaptimmune Therapeutics Company Profile
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets.
Recommended Story: Stock Market – What is a circuit breaker?
Want to see what other hedge funds are holding ADAP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Adaptimmune Therapeutics plc (NASDAQ:ADAP).
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.